Screening of a natural compound library identifies emodin, a natural compound from *Rheum palmatum* Linn that inhibits DPP4

Zhaokai Wang [1,2] , **Longhe Yang** [3] , **Hu Fan** [4] , **Peng Wu** [4] , **Fang Zhang** [4] , **Chao Zhang** [5] , **Wenjie Liu** [Corresp., 6] , **Min Li** [Corresp. 1]

[1] College of Life Sciences, Fujian Normal University, Fuzhou, P. R. China

[2] Engineering Research Center of Marine Biological Resource Comprehensive Utilization,, Third Institute of Oceanography, State Oceanic Administration,, Xiamen, P. R. China

[3] Engineering Research Center of Marine Biological Resource Comprehensive Utilization,, Third Institute of Oceanography, State Oceanic Administration, Subject Areas, Xiamen, P. R. China

[4] Engineering Research Center of Marine Biological Resource Comprehensive Utilization,, Third Institute of Oceanography, State Oceanic Administration, Xiamen, P. R. China

[5] Engineering Research Center of Marine Biological Resource Comprehensive Utilization,, Third Institute of 10 Oceanography, State Oceanic Administration, Xiamen, P. R. China

[6] Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen, P. R. China

Corresponding Authors: Wenjie Liu, Min Li
Email address: wjliu@xmu.edu.cn, mli@fjnu.edu.cn

Historically, Chinese herbal medicines have been widely used in the treatment of hyperglycemia, but the mechanisms underlying their effectiveness remain largely unknown. Here, we screened a compound library primarily comprising natural compounds extracted from herbs and marine organisms. The results showed that emodin, a natural compound from *Rheum palmatum* Linn, inhibited DPP4 activity with an in vitro IC_{50} of 5.76 μM without inhibiting either DPP8 or DPP9. A docking model revealed that emodin binds to DPP4 protein through Glu205 and Glu206, although with low affinity. Moreover, emodin treatment (3, 10 and 30 mg/kg, P.O.) in mice decreased plasma DPP4 activity in a dose-dependent manner. Our study suggests that emodin inhibits DPP4 activity and may represent a novel therapeutic for the treatment of type 2 diabetes.

1   PEER-REVIEWED

2   Screening of a natural compound library identifies
3   emodin, a natural compound from *Rheum palmatum*
4   Linn that, inhibits DPP4

5   **Zhaokai Wang[1,2], Longhe Yang[2], Fan Hu[2], Peng Wu[2], Fang Zhang[2], Chao Zhang[2],Wenjie Liu[3]*and Min**
6   **Li[1]***

7   Author and article information

8   [1] College of Life Sciences, Fujian Normal University. Fuzhou, 350007, China;

9   [2] Engineering Research Center of Marine Biological Resource Comprehensive Utilization, Third Institute of Oceanography, State
10   Oceanic Administration, Xiamen, Fujian 361005, P. R. China;

11   [3] Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University,
12   Xiamen, Fujian, 361102, P. R. China

13   E-Mails: wang@tio.org.cn (Z.W.); longheyang@tio.org.cn (L.Y.); fhu@tio.org.cn (F.H.); pwu@tio.org.cn (P.W.);
14   fzhang@tio.org.cn (F.Z); czhang@tio.org.cn (C.Z.).

15   *Corresponding author:

16   wjliu@xmu.edu.cn(W.L.),Tel.: +86-592-2881180; mli@fjnu.edu.cn(M.L.), Tel. +86-591-22867555.

17   Abstract

18   Historically, Chinese herbal medicines have been widely used in the treatment of hyperglycemia, but
19   the mechanisms underlying their effectiveness remain largely unknown. Here, we screened a compound
20   library primarily comprising natural compounds extracted from herbs and marine organisms. The
21   results showed that emodin, a natural compound from *Rheum palmatum* Linn, inhibited DPP4 activity
22   with an in vitro IC_{50} of 5.76 μM without inhibiting either DPP8 or DPP9. A docking model revealed that
23   emodin binds to DPP4 protein through Glu205 and Glu206, although with low affinity. Moreover,
24   emodin treatment (3, 10 and 30 mg/kg, P.O.) in mice decreased plasma DPP4 activity in a dose-
25   dependent manner. Our study suggests that emodin inhibits DPP4 activity and may represent a novel
26   therapeutic for the treatment of type 2 diabetes.

27   Main article text

28   Introduction

29   Type 2 diabetes mellitus (T2DM) is a metabolic disease associated with insulin resistance and pancreatic
30   β-cell failure (Defronzo 2009). Therefore, enhancing pancreatic insulin secretion while protecting

31   pancreatic β-cells represents a promising therapeutic approach for the treatment of type 2 diabetes.
32   Glucagon-like peptide 1 (GLP-1) is one of the incretin hormones released from cells in the gastrointestinal
33   tract in response to nutrient absorption. Incretin hormones, especially GLP-1, regulate post-prandial
34   insulin secretion by inhibiting glucagon release and stimulating insulin biosynthesis and secretion
35   (Baggio & Drucker 2007). In T2DM patients, GLP-1 is critical for glucose homeostasis (Mulvihill &
36   Drucker 2014).
37   Dipeptidyl peptidase 4 (DPP4), which was first identified by Hopsu-Havuand Glenner, rapidly
38   degrades the active form of GLP-1 (GLP-1$_{7-36}$) to inactive GLP-1$_{9-36}$ within minutes in vivo (Hopsu-Havu
39   & Glenner 1966; Mulvihill & Drucker 2014). DPP4 is commonly expressed as two forms: a membrane-
40   associated and soluble circulating protein and a cleaved protein containing either analanine or proline at
41   position 2 (Lambeir et al. 2003). Therefore, a DPP4 inhibitor could potentially increase the effect of intact
42   GLP-1, thus prolonging its anti-diabetic effects (Smith et al. 2014).

43   Although several DPP4 inhibitors such as sitagliptin (MK-0431) (Kim et al. 2005), vildagliptin (LAF-
44   237) (Villhauer et al. 2003), saxagliptin (BMS-477118) (Augeri et al. 2005), alogliptin (SYR-322) (Feng et al.
45   2007) and linagliptin (BI-1356) (Eckhardt et al. 2007) have been approved for the treatment of T2DM, few
46   natural compounds have been reported to exert DPP4 inhibitory activity (Geng et al. 2013).
47   Traditional Chinese medicine (TCM) has been used in the clinical treatment of diabetes and related
48   complications for centuries (Wang & Chiang 2012; Xie & Du 2011). *Radix Astragali* (Wang et al. 2009) and
49   *Radix Rehmanniae* (Huang et al. 2010) are TCMs with both hypoglycemic and anti-inflammatory activities
50   as reviewed by Xie et al. (Xie & Du 2011) and Liu et al.(Liu et al. 2004). However, the underlying
51   mechanisms of the effective components are largely unknown because of the poor characterization of
52   Chinese medicine. Herein, we screened a small library of natural products from Chinese herbal medicines
53   and marine organisms to identify new molecules that inhibit DPP4 activity. In our research, we
54   discovered that emodin from the herb *Rheum palmatum* Linn inhibited DPP4 activity with an IC$_{50}$ of 5.76
55   μM without inhibiting of either DPP8 or DPP9. Moreover, oral administration of emodin decreased DPP4
56   activity in a dose-dependent manner in mice.

57   **Materials and Methods**

58   *Materials*

59   The natural product library derived from Chinese herbs was purchased from Selleck Chemicals (Cat#
60   L1400, Shanghai, China). Marine-derived compounds were isolated and purified from marine organisms
61   in our lab.

62   *DPP4 activity assay*

63   The DPP4 screening assay was conducted using a DPP4 inhibitor screening assay kit (Cayman Chemical,
64   Ann Arbor, MI), following the manufacturer's protocol. Briefly, 30 μl of diluted assay buffer, 10 μl of
65   diluted DPP4, and 10 μl of inhibitor were added to a 96-well plate. The reaction was initiated by adding
66   50 μl of diluted substrate solution to all of the wells, and this was followed by incubation with a plate
67   cover at 37°C for 30 minutes. After incubation, the fluorescence was read using an excitation wavelength
68   of 360 nm and an emission wavelength of 460 nm.

69   *DPP8 activity assay*

70   A DPP8 assay kit was purchased from BPS Bioscience (Cat# 800208), and the assay protocol was followed
71   to test for inhibitory activity on DPP8. Briefly, DPP substrate 1 was diluted to make a 100 μM stock
72   solution, and DPP8 protein was diluted in DPP assay buffer to 2 ng/μl (20 ng/reaction). For the tested
73   compounds, 10 μl of diluted DPP8 protein, 5 μl of diluted DPP substrate 1, 84 μl of DPP assay buffer and

74   1 µl of inhibitor were added into the assay system for a total volume of 100 µl. The reaction mixtures
75   were prepared in duplicate on a 96-well plate and incubated at room temperature for 10 minutes. The
76   plate was read on an Envision plate reader (Perkin-Elmer) capable of excitation at 365 nm and emission
77   detection at 460 nm.

78   *DPP9 activity assay*

79   A DPP9 assay kit was purchased from BPS Bioscience (Cat# 800209), and the assay protocol was followed
80   to test for inhibitory activity against DPP9. Briefly, DPP substrate 1 was diluted to make a 100 µM stock
81   solution, and DPP9 protein was diluted in DPP assay buffer to 2 ng/µl (20 ng/reaction). For the tested
82   compounds, 10 µl of diluted DPP9 protein, 5 µl of diluted DPP substrate 1, 84 µl of DPP assay buffer and
83   1 µl of inhibitor were added into the assay system for a total volume of 100 µl. The reaction mixtures
84   were prepared in duplicate on a 96-well plate and incubated at room temperature for 10 minutes. The
85   plate was read on an Envision plate reader (Perkin-Elmer) capable of excitation at 365 nm and emission
86   detection at 460 nm.

87   *Docking assay*

88   Docking of compounds to the DPP4 active site was modeled using the Glide package. The 3-dimensional
89   model of DPP4 (PDB code: 2ONC) was used in the molecular modeling experiment (Huang et al. 2010).
90   Compounds were docked onto the DPP4 binding site at a position in which either the substrate or small
91   molecule inhibitors were fitted into the active pocket. Bond formation between the compound and the
92   DPP4 active site was dynamically simulated.

93   *Dialysis assay*

94   Dialysis assay was performed using Slide-A-Lyzer Dialysis Cassettes (Pierce, Shanghai, China). Briefly, 2
95   mg DPP4 protein was incubated with emodin or dimethyl sulfoxide (DMSO) in 4 ml diluted assay buffer
96   for 10 minutes at 37°C. Mixed reaction solution was loaded onto a dialysis cartridge using a syringe and
97   incubated at 4°C for 8 h. The samples were removed from Dialysis Cassettes by syringes for DPP4 assay.

98   *Animal study*

99   Balb/c mice and ob/ob (-/-) mice were purchased from the Shanghai SLAC Laboratory Animal Co. Ltd.
100   (Shanghai, China) and maintained in an air-conditioned room at 20–25°C under a 12 h dark/light cycle
101   and fed certified standard chow and tap water ad libitum. Experiments were conducted in compliance
102   with the Guide for the Care and Use of Laboratory Animals. Mice were orally administered with emodin
103   (3, 10, or 30 mg /kg) and had their blood collected at 0.5, 1, 2, and 4 hours after emodin treatment. The
104   samples were subjected to plasma isolation immediately after collection. Plasma samples were tested for
105   DPP4 activity with a DPP4-Glo assay kit (Promega, Beijing, China) according to the manufacturer's
106   protocol. The experimental protocol was approved by Animal Care and Use Committee of Xiamen
107   University(XM2015030514).

108   *Data analysis*

109   Results are presented as the mean ± standard error (SEM). Differences between the groups were analyzed
110   using multiple variances (one-way ANOVA or two-way ANOVA) followed by Bonferroni's test, with

111 GraphPad Prism 5 software (GraphPad Software, San Diego, CA, USA). Differences were considered to
112 be statistically significant at p < 0.05.

113 **Results and Discussion**

114 *Emodin inhibits DPP4 activity in vitro*

115 To screen for novel DPP4 inhibitors from natural compounds, we established a natural compound library
116 comprising 155 naturally derived compounds, in which 131 were isolated and purified from Chinese
117 herbal medicines, and 24 were from marine organisms. DPP4 screening was first conducted on these 155
118 natural compounds by following a DPP4 screening assay kit protocol. All compounds (10 μM) were
119 screened for DPP4 inhibitory activity. The results suggested that emodin showed greater than 50%
120 inhibition in the DPP4 activity assay at 10 μM. Two other compounds were ruled out because of auto-
121 fluorescence (Figure 1A).
122   To further validate this finding, a dose response experiment was performed to test the inhibitory
123 activity of emodin on DPP4. Emodin was shown to inhibit DPP4 activity in vitro with an IC_{50} of 5.76 μM
124 and Ki of 0.85 (Figure 1B). The DPP4 antagonist sitagliptin was used as a positive control, which showed
125 an IC_{50} of 21.78 nM (Figure 1C), a value similar to those from previous reports (Kim et al. 2005).
126   Considering that emodin is an anthraquinone, and many naturally occurring anthraquinones have
127 been identified as having anti-diabetes activity (Chen et al. 2015; Lin et al. 2015; Ramos-Zavala et al. 2011;
128 Wu et al. 2014), we wondered whether this class of compounds, such as Aloe-emodin, rheochrysidin,
129 chrysophanol and rhein, might inhibit DPP4 activity.

130 *Anthraquinone compounds inhibit DPP4 activity but not DPP8 or DPP9 activity*

131 We further investigated a series of anthraquinone compounds in the DPP4 activity assay to identify
132 potent DPP4 inhibitors in this class. Aloe-emodin, rheochrysidin, chrysophanol and rhein were tested by
133 using the same DPP4 assay format (Table 1). The IC_{50} of each compound is listed, with aloe-emodin
134 showing an IC_{50} of 16.02 μM and rhein showing an IC_{50} of 23.06 μM. The IC_{50} values of rheochrysidin and
135 chrysophanol were greater than 100 μM (Table 1). These results showed that emodin was the most
136 effective anthraquinone in inhibiting DPP4 activity. Because of the high similarity between DPP4 and
137 DPP8/9 and the reported toxicity of DPP8 or DPP9 inhibition in animal studies (Lankas et al. 2005), we
138 tested the anthraquinone compounds in DPP8 and DPP9 activity assays. All of the compounds were
139 tested at 100 μM, and none showed activity against either DPP8 or DPP9.   Rhein showed a very weak
140 activity on DPP8, with an IC50 greater than 100 μM. The biological function of rhein on DPP8 is minimal
141 compared to other DPP8 inhibitors. This result suggests that emodin is a relatively selective inhibitor
142 against DPP4 (Figure 2). To confirm this finding, we conducted a molecular docking assay.

143 *Emodin binds to Glu205 and Glu206 of DPP4 protein in a docking model*

144 The active site of DPP4 consists of Arg125, Glu205, Glu206, Typ547, Trp629, Tyr666, and His740
145 according to the crystal structure template of DPP4 with a small molecular inhibitor (PDB code: 2ONC)
146 (Feng et al. 2007). Our docking model revealed that the negatively charged hydroxyl group of emodin is
147 engaged in tight H-bonding with Glu205 and Glu206 (Fig. 3A), suggesting a mechanism of binding of
148 emodin to the DPP4 active site. The binding modes showed that emodin was bound to the active site of
149 DPP4 with the hydroxyl moiety but did not form hydrogen bonds with other amino moieties such as
150 Tyr547 or Trp629 (Ji et al. 2014; Kim et al. 2005）, which may affect the activity of emodin. The
151 compounds with similar structure as emodin that have hydroxyl group at similar site could also form H-

152   bond with Glu205 and Glu206, and these compounds (aloe-emodin and rhein) also showed DPP4
153   inhibitory activity. In comparison, compounds without the hydroxyl group at R2 location (rheochrysidin
154   and chrysophanol) lack the ability to form H-bond with DPP4 at active site, thus they showed weakest
155   DPP4 inhibitory activity.Following dialysis assay suggested emodin binding to the DPP4 active site in a
156   reversible manner (Fig. 3B). To evaluate the DPP4 inhibitory activity of emodin in vivo, we orally
157   administered emodin to Balb/c mice.

158   *Emodin inhibits DPP4 activity in vivo*

159   DPP4, also known as adenosine deaminase complexing protein 2 or T-cell activation antigen CD26, is a
160   member of the large family of proteases. DPP4 is associated with immune regulation, signal transduction
161   and apoptosis. Recent reports shown that DPP4 correlates closely to diabetes and cancer. Our labs have
162   focused attention on DPP4 for the screening of inhibitors, such as emodin from **Rheum palmatum** Linn.
163   As a natural product and active ingredient of various Chinese herbs, emodin exerts its anti-diabetic
164   effects partially by upregulating the expression of the pancreas L-type calcium channel in streptozotocin
165   (STZ)-induced dyslipidemic diabetic rats (Zhao et al. 2009) and by inhibiting 11 beta-hydroxysteroid
166   dehydrogenase type 1 (11β-HSD1) activity in diet-induced obese (DIO) mice (Feng et al. 2010; Wang et al.
167   2012). Xue et al. have also reported that emodin exerts anti-diabetic effects against PPAR-gamma in mice
168   either administered a high-fat diet or treated with low-dose STZ to induce diabetes (Xue et al. 2010). Song
169   et al. have reported that emodin regulates glucose homeostasis in vivo via AMP-activated kinase (AMPK)
170   activation (Song et al. 2013). Emodin has also been shown to decrease blood glucose in rats with diabetes
171   induced by low-dose STZ combined with high energy intake (Wu et al. 2014). These data clearly show that
172   emodin exerts anti-hypoglycemic effects through diverse mechanisms, which is in line with the results of
173   our screening analysis.

174   To test the inhibitory activity of emodin on DPP4 in vivo, an animal experiment was conducted by oral
175   administration of emodin (3, 10 and 30 mg/kg, P.O.) to Balb/c mice, followed by plasma collection at
176   different time points to measure DPP4 activity in the blood. Plasma samples were collected at 0, 0.5, 1, 2
177   and 4 hours after the oral dose of emodin, and plasma DPP4 activity was measured with a DPP4-Glo
178   assay kit. The results suggested that emodin treatment (3, 10 and 30 mg/kg, P.O.) in mice decreased the
179   plasma DPP4 activity in a dose-dependent manner (Fig. 4). The lowest does of emodin (3 mg/kg)
180   decreased plasma DPP4 activity from baseline, although these levels rebounded after 1 hour, whereas 10
181   and 30 mg/kg doses of emodin decreased plasma DPP4 activity and maintained the lower levels until 2
182   hours post-treatment (Fig. 4). This dose-dependent manner is probably due to the pharmacokinetics of
183   emodin, and 10 and 30 mg/kg have maximized the pharmacokinetic coverage, while 3 mg/kg emodin is
184   only sufficient to maintain 1 hour DPP4 inhibition in vivo. In the subsequent experiment, emodin (30
185   mg/kg, P.O.) was administered on Balb/C mice or ob/ob (-/-) mice. The DPP4 activity, blood glucoselevels
186   and GLP-1 activity were tested 0, 1, 2, 4, 8 hours after administration. The baseline level of DPP4 was
187   higher in ob/ob (-/-) mice compared to Balb/C mice, and the data demonstrated a significant
188   downregulation of DPP4 activity after emodin oral administration in both Balb/C mice and ob/ob (-/-)
189   mice (Fig. 5A). This downregulation maintained 2 hours in Balb/C mice, and 4 hours in ob/ob (-/-) mice,
190   which rebounded afterwards (Fig. 5A). Meanwhile, emodin down-regulated blood glucose level after oral
191   administration. In both Balb/C mice and ob/ob (-/-) mice, emodin treatment significantly downregulated
192   blood glucose levels from baseline (Fig. 5B), and this downregulation maintained for 4 hours post
193   treatment, and the blood glucose levels returned to baseline 8 hours after treatment. Plasma GLP-1
194   activity was also measured. GLP-1 has a low baseline activity and emodin showed marginal effect on

195 plasma GLP-1 activity (Fig. 5C). These results demonstrate that emodin inhibits DPP4 activity in vivo,
196 which may contribute to its anti-diabetic properties.

197   Emodin has been detected in various Chinese herbs and is efficacious against inflammatory disorders
198 and cancer (Shrimali et al. 2013; Wei et al. 2013) and liver cirrhosis (Woo et al. 2002); furthermore, emodin
199 has demonstrated   immunosuppressive (Kuo et al. 2001) and antibacterial (Wang & Chung 1997)
200 properties. Although many studies have shown the effects of emodin on metabolic abnormalities
201 (especially diabetes), the molecular mechanisms involved have not been thoroughly studied. Our study
202 shows for the first time that emodin is a selective DPP4 inhibitor both in vitro and in vivo, which may
203 explain the anti-diabetes effects of this compound.

204   The toxicity of emodin should also be paid attention to and it has been reported in the previous
205 publications（National Toxicology，2001；Wang et al. 1997）. In these reports, there was no evidence of
206 carcinogenic activity of emodin either in male F344/N rats or female B6C3F1 mice. Although emodin
207 exposure resulted in increased incidences of renal tubule pigmentation in male and female mice and
208 increased incidences of nephropathy in female mice, the emodin doses used in these reports (280 to 2,500
209 ppm) were much higher than the emodin dose in our reports. Our highest in vivo dose 30 mg/kg
210 (equivalent to 30 ppm) is almost one ninth of the lowest dose used in these reports. However, this brings
211 an attention to the chronic toxicity of emodin in the treatment of diabetes in the future. On the other hand,
212 some reports have addressed that emodin isolated from rhubarb may have anti-cancer effects on a few
213 human cancers (National Toxicology 2001).

214 **Conclusions**

215 DPP4 is a well-characterized therapeutic target for type II diabetes treatment, and there have been
216 extensive drug discovery activities reported in this area. However, very few literature has reported
217 natural compounds with activity against DPP4 (Fan et al. 2013). The current study was the first to screen
218 a natural compound library consisting of Chinese herbal medicines and marine organisms, with the goal
219 of identifying novel small molecules that inhibit DPP4. As a result, we discovered that emodin, a
220 compound belonging to the anthraquinone family, selectively inhibited in vitro DPP4 activity with an
221 IC50 of 5.7 μM.

222   To further understand the binding mechanism of emodin and DPP4, we conducted a molecular
223 docking model by simulating the emodin binding mode at the DPP4 active site. The docking assay
224 revealed that emodin interacts with the DPP4 active site and forms H-bonds with Glu205 and Glu206 at
225 the active site of DPP4.

226 Based on the in vitro data and the docking model, we subsequently conducted animal experiment by
227 orally administering emodin to Balb/C mice and ob/ob (-/-) mice. Plasma DPP4 activity was inhibited by
228 emodin administration in a dose-dependent manner, and the blood glucose levels were decreased in both
229 mice strains.

230   Together, these results suggest that emodin is a small molecule inhibitor of DPP4, showing activity
231 both in vitro and in vivo. Emodin, as a novel anti-hypoglycemic compound, may stimulate new drug
232 discovery for the treatment of type 2 diabetes.

233 **Supplemental Information**

234   Raw data of screening a natural compound library

235   Raw data of IC50 analysis

236   Raw data of plasma DPP4 activity analysis

237   **Additional Information and Declarations**

238   **Data Availability**

239   The following information was supplied regarding data availability:

240   The raw data has been supplied as a <u>Supplemental File.</u>

241   **References**

242   1.   Augeri DJ, Robl JA, Betebenner DA, Magnin DR, Khanna A, Robertson JG, Wang A,
243   Simpkins LM, Taunk P, Huang Q, Han SP, Abboa-Offei B, Cap M, Xin L, Tao L, Tozzo
244   E, Welzel GE, Egan DM, Marcinkeviciene J, Chang SY, Biller SA, Kirby MS, Parker
245   RA, and Hamann LG. 2005. Discovery and preclinical profile of Saxagliptin (BMS-
246   477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for
247   the treatment of type 2 diabetes. *J Med Chem* 48:5025-5037. 10.1021/jm050261p

248   2.   Baggio LL, and Drucker DJ. 2007. Biology of incretins: GLP-1 and GIP. *Gastroenterology*
249   132:2131-2157. 10.1053/j.gastro.2007.03.054

250   3.   Chen T, Zheng LY, Xiao W, Gui D, Wang X, and Wang N. 2015. Emodin ameliorates high
251   glucose induced-podocyte epithelial-mesenchymal transition in-vitro and in-vivo. *Cell*
252   *Physiol Biochem* 35:1425-1436. 10.1159/000373963

253   4.   Defronzo RA. 2009. Banting Lecture. From the triumvirate to the ominous octet: a new
254   paradigm for the treatment of type 2 diabetes mellitus. *Diabetes* 58:773-795.
255   10.2337/db09-9028

256   5.   Eckhardt M, Langkopf E, Mark M, Tadayyon M, Thomas L, Nar H, Pfrengle W, Guth B,
257   Lotz R, Sieger P, Fuchs H, and Himmelsbach F. 2007. 8-(3-(R)-aminopiperidin-1-yl)-7-
258   but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylme thyl)-3,7-dihydropurine-2,6-dione
259   (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor
260   for the treatment of type 2 diabetes. *J Med Chem* 50:6450-6453. 10.1021/jm701280z

261   6.   Fan J, Johnson MH, Lila MA, Yousef and Mejia EG.2013. Berry and Citrus Phenolic
262   Compounds Inhibit Dipeptidyl Peptidase IV: Implications in Diabetes Management. *Evid*
263   *Based Complement Alternat Med* 2013:479505. 10.1155/2013/479505

264   7.   Feng J, Zhang Z, Wallace MB, Stafford JA, Kaldor SW, Kassel DB, Navre M, Shi L, Skene
265   RJ, Asakawa T, Takeuchi K, Xu R, Webb DR, and Gwaltney SL, 2nd. 2007. Discovery
266   of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl
267   peptidase IV. *J Med Chem* 50:2297-2300. 10.1021/jm070104l

268   8.   Feng Y, Huang SL, Dou W, Zhang S, Chen JH, Shen Y, Shen JH, and Leng Y. 2010.
269   Emodin, a natural product, selectively inhibits 11beta-hydroxysteroid dehydrogenase type

270   1 and ameliorates metabolic disorder in diet-induced obese mice. *Br J Pharmacol*
271   161:113-126. 10.1111/j.1476-5381.2010.00826.x

272   9.   Geng Y, Lu ZM, Huang W, Xu HY, Shi JS, and Xu ZH. 2013. Bioassay-guided isolation of
273   DPP-4 inhibitory fractions from extracts of submerged cultured of Inonotus obliquus.
274   *Molecules* 18:1150-1161. 10.3390/molecules18011150

275   10. Hopsu-Havu VK, and Glenner GG. 1966. A new dipeptide naphthylamidase hydrolyzing
276   glycyl-prolyl-beta-naphthylamide. *Histochemie* 7:197-201.

277   11. Huang WJ, Niu HS, Lin MH, Cheng JT, and Hsu FL. 2010. Antihyperglycemic effect of
278   catalpol in streptozotocin-induced diabetic rats. *J Nat Prod* 73:1170-1172.
279   10.1021/np9008317

280   12. Ji X, Xia C, Wang J, Su M, Zhang L, Dong T, Li Z, Wan X, Li J, Li J, Zhao L, Gao Z, Jiang
281   H, and Liu H. 2014. Design, synthesis and biological evaluation of 4-fluoropyrrolidine-2-
282   carbonitrile and octahydrocyclopenta[b]pyrrole-2-carbonitrile derivatives as dipeptidyl
283   peptidase IV inhibitors. *Eur J Med Chem* 86:242-256. 10.1016/j.ejmech.2014.08.059

284   13. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE,
285   Leiting B, Lyons K, Marsilio F, McCann ME, Patel RA, Petrov A, Scapin G, Patel SB,
286   Roy RS, Wu JK, Wyvratt MJ, Zhang BB, Zhu L, Thornberry NA, and Weber AE. 2005.
287   (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- yl]-1-
288   (2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV
289   inhibitor for the treatment of type 2 diabetes. *J Med Chem* 48:141-151.
290   10.1021/jm0493156

291   14. Kuo YC, Tsai WJ, Meng HC, Chen WP, Yang LY, and Lin CY. 2001. Immune reponses in
292   human mesangial cells regulated by emodin from Polygonum hypoleucum Ohwi. *Life Sci*
293   68:1271-1286.

294   15. Lambeir AM, Durinx C, Scharpe S, and De Meester I. 2003. Dipeptidyl-peptidase IV from
295   bench to bedside: an update on structural properties, functions, and clinical aspects of the
296   enzyme DPP IV. *Crit Rev Clin Lab Sci* 40:209-294. 10.1080/713609354

297   16. Lankas GR, Leiting B, Roy RS, Eiermann GJ, Beconi MG, Biftu T, Chan CC, Edmondson
298   S, Feeney WP, He H, Ippolito DE, Kim D, Lyons KA, Ok HO, Patel RA, Petrov AN,
299   Pryor KA, Qian X, Reigle L, Woods A, Wu JK, Zaller D, Zhang X, Zhu L, Weber AE,
300   and Thornberry NA. 2005. Dipeptidyl peptidase IV inhibition for the treatment of type 2
301   diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. *Diabetes*
302   54:2988-2994.

303   17. Lin YJ, Hu G, Li KJ, Zhao YF, Wei J, and Zhen YZ. 2015. The protection of Rhein lysinate
304   to liver in diabetic mice induced by high-fat diet and streptozotocin. *Arch Pharm Res*
305   38:885-892. 10.1007/s12272-014-0423-4

306   18. Liu JP, Zhang M, Wang WY, and Grimsgaard S. 2004. Chinese herbal medicines for type 2
307   diabetes mellitus. *Cochrane Database Syst Rev*:CD003642.
308   10.1002/14651858.CD003642.pub2

309   19.   Mulvihill EE, and Drucker DJ. 2014. Pharmacology, physiology, and mechanisms of action
310   of dipeptidyl peptidase-4 inhibitors. *Endocr Rev* 35:992-1019. 10.1210/er.2014-1035

311   20.   National Toxicology P. 2001. NTP Toxicology and Carcinogenesis Studies of EMODIN
312   (CAS NO. 518-82-1) Feed Studies in F344/N Rats and B6C3F1 Mice. *Natl Toxicol*
313   *Program Tech Rep Ser* 493:1-278.

314   21.   Ramos-Zavala MG, Gonzalez-Ortiz M, Martinez-Abundis E, Robles-Cervantes JA,
315   Gonzalez-Lopez R, and Santiago-Hernandez NJ. 2011. Effect of diacerein on insulin
316   secretion and metabolic control in drug-naive patients with type 2 diabetes: a randomized
317   clinical trial. *Diabetes Care* 34:1591-1594. 10.2337/dc11-0357

318   22.   Shrimali D, Shanmugam MK, Kumar AP, Zhang J, Tan BK, Ahn KS, and Sethi G. 2013.
319   Targeted abrogation of diverse signal transduction cascades by emodin for the treatment
320   of inflammatory disorders and cancer. *Cancer Lett* 341:139-149.
321   10.1016/j.canlet.2013.08.023

322   23.   Smith EP, An Z, Wagner C, Lewis AG, Cohen EB, Li B, Mahbod P, Sandoval D, Perez-
323   Tilve D, Tamarina N, Philipson LH, Stoffers DA, Seeley RJ, and D'Alessio DA. 2014.
324   The role of beta cell glucagon-like peptide-1 signaling in glucose regulation and response
325   to diabetes drugs. *Cell Metab* 19:1050-1057. 10.1016/j.cmet.2014.04.005

326   24.   Song P, Kim JH, Ghim J, Yoon JH, Lee A, Kwon Y, Hyun H, Moon HY, Choi HS,
327   Berggren PO, Suh PG, and Ryu SH. 2013. Emodin regulates glucose utilization by
328   activating AMP-activated protein kinase. *J Biol Chem* 288:5732-5742.
329   10.1074/jbc.M112.441477

330   25.   Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, Mangold BL,
331   Russell ME, and Hughes TE. 2003. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-
332   (S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV
333   inhibitor with antihyperglycemic properties. *J Med Chem* 46:2774-2789.
334   10.1021/jm030091l

335   26.   Wang HH, and Chung JG. 1997. Emodin-induced inhibition of growth and DNA damage in
336   the Helicobacter pylori. *Curr Microbiol* 35:262-266.

337   27.   Wang HJ, and Chiang BH. 2012. Anti-diabetic effect of a traditional Chinese medicine
338   formula. *Food Funct* 3:1161-1169. 10.1039/c2fo30139c

339   28.   Wang N, Zhang D, Mao X, Zou F, Jin H, and Ouyang J. 2009. Astragalus polysaccharides
340   decreased the expression of PTP1B through relieving ER stress induced activation of
341   ATF6 in a rat model of type 2 diabetes. *Mol Cell Endocrinol* 307:89-98.
342   10.1016/j.mce.2009.03.001

343   29.   Wang YJ, Huang SL, Feng Y, Ning MM, and Leng Y. 2012. Emodin, an 11beta-
344   hydroxysteroid dehydrogenase type 1 inhibitor, regulates adipocyte function in vitro and
345   exerts anti-diabetic effect in ob/ob mice. *Acta Pharmacol Sin* 33:1195-1203.
346   10.1038/aps.2012.87

347 30. Wei WT, Lin SZ, Liu DL, and Wang ZH. 2013. The distinct mechanisms of the antitumor
348   activity of emodin in different types of cancer (Review). *Oncol Rep* 30:2555-2562.
349   10.3892/or.2013.2741

350 31. Woo SW, Nan JX, Lee SH, Park EJ, Zhao YZ, and Sohn DH. 2002. Aloe emodin suppresses
351   myofibroblastic differentiation of rat hepatic stellate cells in primary culture. *Pharmacol*
352   *Toxicol* 90:193-198.

353 32. Wu Z, Chen Q, Ke D, Li G, and Deng W. 2014. Emodin protects against diabetic
354   cardiomyopathy by regulating the AKT/GSK-3beta signaling pathway in the rat model.
355   *Molecules* 19:14782-14793. 10.3390/molecules190914782

356 33. Xie W, and Du L. 2011. Diabetes is an inflammatory disease: evidence from traditional
357   Chinese medicines. *Diabetes Obes Metab* 13:289-301. 10.1111/j.1463-
358   1326.2010.01336.x

359 34. Xue J, Ding W, and Liu Y. 2010. Anti-diabetic effects of emodin involved in the activation
360   of PPARgamma on high-fat diet-fed and low dose of streptozotocin-induced diabetic
361   mice. *Fitoterapia* 81:173-177. 10.1016/j.fitote.2009.08.020

362 35. Zhao XY, Qiao GF, Li BX, Chai LM, Li Z, Lu YJ, and Yang BF. 2009. Hypoglycaemic and
363   hypolipidaemic effects of emodin and its effect on L-type calcium channels in
364   dyslipidaemic-diabetic rats. *Clin Exp Pharmacol Physiol* 36:29-34. 10.1111/j.1440-
365   1681.2008.05051.x

366

Figure 1

Emodin was found to inhibit DPP4 activity after screening a natural compound library.

Figure 2

Anthraquinone compounds do not inhibit either (a) DPP8 or (b) DPP9.

Figure 3

Docking model reveals the binding mode of emodin to DPP4 protein.

Figure 4

Emodin treatment (3, 10 and 30 mg/kg, P.O.) in mice decreased the plasma DPP4 activity in a dose-dependent manner.

Figure 5

Emodin treatment in mice

Table 1(on next page)

Anthraquinone compounds inhibit DPP4 activity

1   **Table 1**

2   Anthraquinone compounds inhibit DPP4 activity.

3

Compound	R_1	R_2	IC_{50} of DPP4 Inhibition (μM)	Ki (μM)
Emodin	-CH$_3$	-OH	5.76±0.42	0.85±0.06
Aloe-emodin	-H	-CH$_2$OH	16.02±4.24	2.37±0.62
Rheochrysidin	-CH$_3$	-OCH$_3$	> 100	-
Chrysophanol	-H	-CH$_3$	> 100	-
Rhein	-H	-COOH	23.06±3.57	3.42±0.53

4   Values **(μM) are means±** SE.

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20